Cantor Fitzgerald Predicts CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will earn ($3.61) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $67.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

A number of other equities analysts have also recently commented on the stock. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Citigroup initiated coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Finally, The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Trading Up 3.5 %

Shares of NASDAQ CLDX opened at $24.61 on Wednesday. Celldex Therapeutics has a twelve month low of $22.17 and a twelve month high of $53.18. The stock has a 50 day moving average of $25.75 and a two-hundred day moving average of $31.76.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC raised its position in Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock worth $639,000 after acquiring an additional 4,967 shares during the last quarter. Mirador Capital Partners LP raised its position in shares of Celldex Therapeutics by 2.9% during the 4th quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company’s stock worth $3,020,000 after purchasing an additional 3,345 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its holdings in Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock valued at $1,449,000 after buying an additional 2,070 shares during the last quarter. Geode Capital Management LLC increased its position in Celldex Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after buying an additional 6,557 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock worth $4,431,000 after acquiring an additional 76,207 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.80% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.